Outcome of Next Major Zantac-Related Lawsuit | Categorical | | | 7 months ago | |
New Scientific Studies Linking Zantac to Cancer by Mid-2025? | Binary | | | 7 months ago | |
Zantac Reintroduction to Market by End of 2024? | Binary | | | 7 months ago | |
Ochre Bio's treatment in clinical trials by 2025? | Binary | | | 8 months ago | |
Ochre Bio hits first partnership milestone by end of 2024? | Binary | | | 8 months ago | |
Clinical trial phase progression of Ochre Bio's treatment by 2026 | Categorical | | | 8 months ago | |
Will uninsured patients purchase Adalimumab-adbm at $550 by Oct 31, 2024? | Binary | | | 5 months ago | |
Number of Zantac Lawsuits Settled in Favor of Plaintiffs by 2024 | Categorical | | | 7 months ago | |
Majority Zantac Lawsuit Wins by GSK and Boehringer in 2024? | Binary | | | 7 months ago | |
Scope expansion of Ochre Bio's treatments by end of 2025 | Categorical | | | 8 months ago | |
Søren Tullin remains at his position through 2024? | Binary | | | 8 months ago | |
Total Boehringer Ingelheim payments to Ochre Bio by end of 2025 | Categorical | | | 8 months ago | |
Stock Price Impact on GSK and Boehringer Post-Zantac Lawsuits by 2024 | Categorical | | | 7 months ago | |
In how many states will Adalimumab-adbm be available at $550 by Nov 30, 2024? | Categorical | | | 5 months ago | |
What will be the market share of Adalimumab-adbm among Humira biosimilars by Dec 31, 2024? | Categorical | | | 5 months ago | |
Will Adalimumab-adbm be available in retail pharmacies nationwide by Dec 31, 2024? | Binary | | | 5 months ago | |
Will Adalimumab-adbm be the lowest-priced Humira version by Dec 31, 2024? | Binary | | | 5 months ago | |
What percentage of uninsured patients will afford Adalimumab-adbm at $550 by Dec 31, 2024? | Categorical | | | 5 months ago | |
